中银国际：升泰格医药目标价至51港元 维持“买入”评级

Core Viewpoint - The report from Zhongyin International indicates that Tigermed (300347)(03347) is facing challenges in the domestic biotechnology industry due to weak demand and financing constraints, impacting project quantity and pricing [1] Group 1: Company Performance - Tigermed's profitability has contracted, but expansion in overseas business is helping to mitigate some of the impacts [1] - The outlook suggests that a recovery in domestic financing and new overseas orders may support gradual performance improvement, although the timing remains uncertain [1] Group 2: Investment Rating - The stock is maintained with a "Buy" rating, and the target price has been raised from HKD 40 to HKD 51 [1]